Literature DB >> 22772395

Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing.

Samrina Rehman1, Yun Xu, Warwick B Dunn, Philip J R Day, Hans V Westerhoff, Royston Goodacre, Ardeshir Bayat.   

Abstract

Dupuytren's disease (DD) is an ill-defined fibroproliferative disorder affecting the palm of the hand, resulting in progressive and irreversible digital contracture. In view of the abnormal gene dysregulation found in DD, and its potential effect on metabolites at a functional level, we chose to examine the metabolic profile involved in DD. Using Fourier transform infrared (FT-IR) spectroscopy to generate metabolic fingerprints of cultured cells, we compared the profiles of DD cords and nodules (1) against the unaffected transverse palmar fascia (internal control), (2) against carpal ligamentous fascia (external control), and (3) against fibroblasts from fat surrounding the nodule and skin overlying the nodule (environmental control). We also determined the effects of serial passaging of the cells on DD fingerprints. Subsequently, gas chromatography-mass spectrometry (GC-MS) was employed for metabolic profiling in order to identify metabolites characteristic of the DD tissue phenotypes. We developed a robust metabolomic analysis procedure of DD using cultured fibroblasts derived from DD tissues. Our carefully controlled culture conditions, combined with assessment of metabolic phenotypes by FT-IR and GC-MS, enabled us to demonstrate metabolic differences between DD and unaffected transverse palmar fascia and between DD and healthy control tissue. In early passage (0-3) the metabolic differences were clear, but cells from subsequent passages (4-6) started to lose this distinction between diseased and non-diseased origin. The dysregulated metabolites we identified were leucine, phenylalanine, lysine, cysteine, aspartic acid, glycerol-3-phosphate and the vitamin precursor to coenzyme A. Early passage DD cells exhibit a clear metabolic profile, in which central metabolic pathways appear to be involved. Experimental conditions have been identified in which these DD data are reproducible. The experimental reproducibility will be useful in DD diagnostics and for DD systems biology.

Entities:  

Mesh:

Year:  2012        PMID: 22772395     DOI: 10.1039/c2mb25173f

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  6 in total

1.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.

Authors:  Liaquat S Verjee; Jennifer S N Verhoekx; James K K Chan; Thomas Krausgruber; Vicky Nicolaidou; David Izadi; Dominique Davidson; Marc Feldmann; Kim S Midwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

2.  Understanding Dupuytren's Disease Using Systems Biology: A Move Away from Reductionism.

Authors:  Samrina Rehman; Philip J R Day; Ardeshir Bayat; Hans V Westerhoff
Journal:  Front Physiol       Date:  2012-08-09       Impact factor: 4.566

Review 3.  Computational tools for the secondary analysis of metabolomics experiments.

Authors:  Sean C Booth; Aalim M Weljie; Raymond J Turner
Journal:  Comput Struct Biotechnol J       Date:  2013-02-06       Impact factor: 7.271

4.  Epidemiological analysis of patients with Dupuytren's disease.

Authors:  Henrique Gonçalves Mansur; Edmo Rodrigues de Oliveira; Cesar Barbosa Gonçalves
Journal:  Rev Bras Ortop       Date:  2017-12-14

5.  Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.

Authors:  Helen B Forrester; Peter Temple-Smith; Seungmin Ham; David de Kretser; Graeme Southwick; Carl N Sprung
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

6.  Matrix and cell phenotype differences in Dupuytren's disease.

Authors:  Marike M van Beuge; Evert-Jan P M Ten Dam; Paul M N Werker; Ruud A Bank
Journal:  Fibrogenesis Tissue Repair       Date:  2016-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.